Respiratory Syncytial Virus, Human
"Respiratory Syncytial Virus, Human" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The type species of PNEUMOVIRUS and an important cause of lower respiratory disease in infants and young children. It frequently presents with bronchitis and bronchopneumonia and is further characterized by fever, cough, dyspnea, wheezing, and pallor.
| Descriptor ID |
D018113
|
| MeSH Number(s) |
B04.820.455.600.670.600.750.730
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Respiratory Syncytial Virus, Human".
Below are MeSH descriptors whose meaning is more specific than "Respiratory Syncytial Virus, Human".
This graph shows the total number of publications written about "Respiratory Syncytial Virus, Human" by people in this website by year, and whether "Respiratory Syncytial Virus, Human" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 1 | 1 | 2 |
| 2013 | 3 | 0 | 3 |
| 2015 | 1 | 1 | 2 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 4 | 1 | 5 |
| 2020 | 4 | 1 | 5 |
| 2021 | 7 | 0 | 7 |
| 2022 | 4 | 0 | 4 |
| 2023 | 13 | 1 | 14 |
| 2024 | 8 | 5 | 13 |
| 2025 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Respiratory Syncytial Virus, Human" by people in Profiles.
-
A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants. J Infect Dis. 2025 Mar 17; 231(3):e478-e487.
-
Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine. Obstet Gynecol. 2025 Feb 01; 145(2):147-156.
-
Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial. Obstet Gynecol. 2025 Feb 01; 145(2):157-167.
-
Epidemiology of human metapneumovirus among children with severe or very severe pneumonia in high pneumonia burden settings: the Pneumonia Etiology Research for Child Health (PERCH) study experience. Clin Microbiol Infect. 2025 Mar; 31(3):441-450.
-
Risk factors for severe respiratory syncytial virus-associated respiratory tract infection in a high HIV prevalence setting, South Africa, 2012 - 2018. BMC Infect Dis. 2024 Oct 09; 24(1):1128.
-
Impact of Respiratory Syncytial Virus and Severe Acute Respiratory Syndrome Coronavirus 2 Coinfection on Clinical Severity and Outcomes Among Children Hospitalized With Lower Respiratory Tract Infections in Soweto, South Africa. Pediatr Infect Dis J. 2025 Feb 01; 44(2):107-111.
-
The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access. Lancet Infect Dis. 2024 Dec; 24(12):e747-e761.
-
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY). Vaccine. 2024 Oct 24; 42(24):126276.
-
The cost of care for children hospitalized with respiratory syncytial virus (RSV) associated lower respiratory infection in Kenya. BMC Public Health. 2024 09 04; 24(1):2410.
-
Standardized Phylogenetic Classification of Human Respiratory Syncytial Virus below the Subgroup Level. Emerg Infect Dis. 2024 Aug; 30(8):1631-1641.